[Seven principles in the treatment of vestibular vertigo and results of the study of VIRTUOSO].

Autor:	Zamergrad MV; Russian Medical Academy for Contin Professional Education, Moscow, Russia; Guta Clinic, Moscow, Russia., Parfenov VA; Sechenov First Moscow State Medical University, Moscow, Russia., Matsnev EI; Institute Medical and Biology Problem, Moscow, Russia., Morozova SV; Sechenov First Moscow State Medical University, Moscow, Russia., Melnikov OA; Guta Clinic, Moscow, Russia., Sigaleva EE; Institute Medical and Biology Problem, Moscow, Russia., Antonenko LM; Sechenov First Moscow State Medical University, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2017; Vol. 117 (12), pp. 106-110.
DOI:	10.17116/jnevro2017117121106-110
Abstrakt:	This article reports the results of the international post-marketing observational program VIRTUOSO aimed at the evaluation of the efficacy of betahistine dihydrochloride at the dose of 48 mg/day for 1-2 months in patients with paroxysmal vertigo of various origins. The clinical response was rated as good, very good or excellent in 74.1% of the patients (p<0.001). Monthly vertigo attack frequency with betahistine decreased in average from 8.0 to 3.0 (p<0.001). Vertigo attack frequency further decreased during the 2-month follow-up after the end of betahistine treatment. No serious adverse effects of betahistine have been reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu